Tracy Cole

Ionis Pharmaceuticals (United States) — United States

Medicine · Health Sciences

15h-index1.9kcitations31works3.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(9), Alzheimer's disease research and treatments(7), Nuclear Receptors and Signaling(7), Neuroinflammation and Neurodegeneration Mechanisms(6), RNA regulation and disease(5)

Publications31 total

Genotypic and phenotypic analysis of 173 patients with extremely rare pathogenic mutations who applied for experimental antisense oligonucleotide treatment
2024· 6 citedOpen Access
Correction: SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex
Acta Neuropathologica Communications·2024· 1 citedOpen Access
Personalized antisense oligonucleotides ‘for free, for life’ — the n-Lorem Foundation
Nature Medicine·2023· 31 cited
SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex
Acta Neuropathologica Communications·2022· 7 citedOpen Access
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
JCI Insight·2021· 127 citedOpen Access
Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model
Annals of Neurology·2021· 76 citedOpen Access
LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes
The EMBO Journal·2020· 102 citedOpen Access
Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment
Molecular Therapy — Nucleic Acids·2020· 22 citedOpen Access
LRRK2 and Rab10 Coordinate Macropinocytosis to Mediate Immunological Responses in Phagocytes
2020· 4 citedOpen Access
Therapeutic IDOL Reduction Ameliorates Amyloidosis and Improves Cognitive Function in APP/PS1 Mice
Molecular and Cellular Biology·2020· 15 citedOpen Access
Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
2019· 10 citedOpen Access
IDOL regulates systemic energy balance through control of neuronal VLDLR expression
Nature Metabolism·2019· 23 citedOpen Access
Protein production is an early biomarker for <scp>RNA</scp>‐targeted therapies
Annals of Clinical and Translational Neurology·2018· 9 citedOpen Access
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Journal of Clinical Investigation·2018· 261 citedOpen Access
2342 Protein production as an early pharmacodynamics biomarker for RNA-targeting therapies
Journal of Clinical and Translational Science·2018Open Access
Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity
Acta Neuropathologica·2018· 125 cited
Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis
Neuron·2017· 209 citedOpen Access
Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss
Molecular Neurodegeneration·2017· 104 citedOpen Access
STARBUCKS: A CASE STUDY OF EFFECTIVE MANAGEMENT IN THE COFFEE INDUSTRY
Journal of International Management Studies·2017
MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models
Journal of Neuroscience·2017· 80 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Holly Kordasiewicz(11), Eric E. Swayze(8), Hien Zhao(8), Andreas Weihofen(6), Andrea J. Tenner(5), Kathleen M. Schoch(4), C. Frank Bennett(4), Timothy M. Miller(4), Katrina L. Paumier(4), Michael Hernandez(4), María Isabel Fonseca(4), Melody Fang(4), Lindsay A. Hohsfield(4), M.D. Martínez del Valle Torres(4), Kim N. Green(4), Rick A. Wetsel(4), A Mortazavi(4), Danielle Graham(3), Esteban Luna(3), Kelvin C. Luk(3)